CAS 1432597-26-6

LDN-212854

Description:

LDN-212854, with the CAS number 1432597-26-6, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is classified as a selective inhibitor of certain enzymes, specifically those involved in the regulation of inflammatory pathways. The compound exhibits a high degree of specificity, which is crucial for minimizing off-target effects and enhancing its efficacy in biological systems. LDN-212854 has been studied for its role in modulating immune responses and may have implications in treating various inflammatory diseases. Its molecular structure features specific functional groups that contribute to its biological activity, and it is typically characterized by its solubility in organic solvents. As with many experimental compounds, ongoing research is essential to fully elucidate its pharmacokinetics, pharmacodynamics, and potential side effects. Overall, LDN-212854 represents a promising candidate in the search for new therapeutic agents targeting inflammatory conditions.

Synonyms:

• Ldn212854

LDN212854

CAS: 1432597-26-6

Formula: C₂₅H₂₂N₆

Purity: 98%

Color and Shape: Solid

Molecular weight: 406.4824

Ref: IN-DA009BPK

LDN-212854

CAS: 1432597-26-6

LDN-212854

Purity: ≥98%

Molecular weight: 406.48g/mol

Ref: 54-BUP00581

LDN-212854

CAS: 1432597-26-6

LDN-212854 (BMP Inhibitor III), a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors.

Formula: C₂₅H₂₂N₆

Purity: 98% - 98.71%

Color and Shape: Solid

Molecular weight: 406.48

Ref: TM-T1900

5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline

Controlled Product

CAS: 1432597-26-6

Formula: C₂₅H₂₂N₆

Color and Shape: Neat

Molecular weight: 406.48

Ref: TR-P481270

LDN-212854

CAS: 1432597-26-6

LDN-212854 is a human immunoglobulin that blocks the Toll-like receptor 4 (TLR4) and inhibits TLR4 signaling pathways. It has been shown to have an effect on several types of cancer, including prostate, breast, and lung cancer. LDN-212854 also has pharmacokinetic properties that allow it to be used in both intravenous and subcutaneous injections. LDN-212854 binds to TLR4 receptors in the cells of the immune system by interfering with the binding of LPS, which is a molecule found on the surface of gram negative bacteria. This prevents activation of TLR4 signaling pathways downstream from LPS binding. LDN-212854 also blocks IL-1β production by inhibiting NFκB activation in response to LPS stimulation.

Formula: C₂₅H₂₂N₆

Purity: Min. 95%

Molecular weight: 406.48 g/mol

Ref: 3D-HHC59726